Unknown PHASE1 INTERVENTIONAL 1-arm NCT04731038

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer

Sponsor: Ruijin Hospital

Conditions Advanced Cervical Cancer

Interventions Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin

Updated 6 times since 2021 Last updated: Sep 16, 2021 Started: Aug 1, 2021 Primary completion: Jul 1, 2022 Completion: Jul 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04731038, this PHASE1 trial focuses on Advanced Cervical Cancer and remains ongoing. Sponsored by Ruijin Hospital, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Oct 2021 — Jul 2024 [monthly]

Recruiting PHASE1
May 2021 — Oct 2021 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Feb 2021 — May 2021 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China